Clinical Study: Dietary Supplement SagaPro Reduces Frequent Urination
REYKJAVIK, Iceland, July 6, 2012 /PRNewswire/ –
A recent clinical study on an Icelandic natural product has shown it to be effective
against “nocturia” in those with low or diminished bladder capacity. Nocturia is the
medical definition of the frequent need to urinate at night. This problem is common among
men with prostate enlargement as well as people of all ages with an overactive bladder.
The product, SagaPro, which is made from the herb “Angelica archangelica”, has been
produced by SagaMedica in Iceland since 2005 and is very popular among nocturia sufferers.
SagaPro has now been clinically studied and a peer-reviewed paper on the study will be
published in the Scandinavian Journal of Urology and Nephrology.
Increased nocturnal bladder volume
The study was performed in Iceland by Encode Ltd. and the whole process lasted one
year. A total of sixty-nine participants, all of them men with “lower urinary tract
symptoms”, which includes prostate enlargement, were required to keep a detailed record of
their nocturnal restroom trips as well as the volume of urine before and after a period of
8 weeks while they took either SagaPro or a placebo.
Findings showed significant results among different subgroups. In that regard, SagaPro
had a pronounced effect on bladder volume and urinary frequency, two factors which affect
the duration and quality of sleep.
“The findings were interesting in many ways. For instance, we saw that SagaPro had a
significant and positive effect on those who had a low or diminished nocturnal bladder
capacity. This knowledge will help us design other studies on SagaPro in the future” says
Dr. Steinthor Sigurdsson, Ph.D. and a researcher at SagaMedica.
Not just a prostate product
The study sheds a light on how SagaPro can help those with prostate enlargement which
affects a majority of men over 60. As SagaPro affects the bladder it indirectly helps men
with prostate enlargement whose main complaint tends to be increased urinary frequency.
The presence of a bladder-relaxing flavonoid in SagaPro had previously suggested the
product worked through a bladder-related mechanism. Successful use by women and young
people with enuresis (bed-wetting) also hinted at this and now the clinical study confirms
that SagaPro affects the bladder, thereby helping sufferers of frequent urination.
Helps international marketing
SagaPro is currently marketed in over 200 retail outlets in the US and Canada. Perla
Bjork Egilsdottir is SagaMedica’s marketing manager: “The positive outcome of the clinical
study will no doubt help us in further marketing SagaPro internationally. We expect the
results to greatly increase our sales since the brand “SagaPro” has now been clinically
verified for both safety and efficacy; not just the product’s individual ingredients,” she
The clinical study on SagaPro is preceded by SagaMedica’s considerable research on the
Angelica herb. This is the 6th peer-reviewed paper the company’s research team publishes
since it was founded in 2000. The paper is entitled: “A parallel, randomised, double
blind, placebo controlled study to investigate the effect of SagaPro on nocturia in men”.
Authors are the MD’s Gudmundur Geirsson and Hrefna Gudmundsdottir and the biochemists
Steinthor Sigurdsson, Perla B. Egilsdottir and professor Sigmundur Gudbjarnason.
Previous studies published by the company research team looked at the herb’s potential
benefits ranging from effects on a neurotransmitter to promote memory health to the
potential uses of Angelica in the battle against cancer. Clinical studies on those
properties are expected to follow in the future.
More information about SagaPro can be found on the company’s website:
1. DOI NUMBER – 10.3109/00365599.2012.695390 [in press]
Photo: http://photos.prnewswire.com/prnh/20120706/543346-a http://photos.prnewswire.com/prnh/20120706/543346-b http://photos.prnewswire.com/prnh/20120706/543346-c